Breaking News

Regeneron & Mammoth Partner on CRISPR Therapies

Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.

Author Image

By: Charlie Sternberg

Associate Editor

Regeneron Pharmaceuticals Inc. and Mammoth Biosciences Inc., have joined forces to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types.   Regeneron is developing adeno-associated viral vectors (AAVs) using antibody-based targeting to enhance delivery of genetic medicine payloads to specific tissues and cell types. Meanwhile, Mammoth is developing novel ultracompact nucleases and associated gene editing systems, with a variety of e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters